Provepharm receives FDA approval for BLUDIGO™ (indigotindisulfonate sodium, USP) Injection
Following GMP certification earned in 2019 for its new production unit, Provepharm now has full control over its production chain for Europe and the US.
New round of funding enables pharma company to make major steps forward in its Horizon 2025 strategy.
Acquisition of high added-value sterile injectable products specialist will enable Provepharm to diversify product portfolio and consolidate position in the US market to prepare for upcoming product launches.
New funding will enable pharmaceutical group to accelerate program of international growth through acquisitions.
Partnership reinforces strategy of independent pharmaceutical group Provepharm Life Solutions and constitutes major step forward in its development.